Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Reduced Complement and Granulocyte Activation by α-Gal Knockout Porcine Pericardium for Bioprosthetic Heart Valves: A Pilot Hemocompatibility Study.

Journal of biomedical materials research. Part A·2026

Same journal

pH-Sensitive Cationic Liposomes for Oridonin and siRNA Co-Delivery to Inhibit Triple-Negative Breast Cancer.

Journal of biomedical materials research. Part A·2026

Same journal

Superelastic Ti-Zr-Nb-Sn Thin Films Fabricated by Magnetron Sputtering: Biocompatibility and Bacterial Biofilm Formation Assessment for Orthopedic Applications.

Journal of biomedical materials research. Part A·2026

Same journal

Edible Sulfonated Soy Protein Microcarriers for Cultivated Meat Cell Expansion.

Journal of biomedical materials research. Part A·2026

Same journal

ROS-Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2-Keap1 Signaling Pathway Activation.

Journal of biomedical materials research. Part A·2026

Same journal

Cellular Insights Into Proangiogenic Activation in Fibroblast and Endothelial Cells by Dual Drug-Loaded Emulsion Electrospun Nanofibers for Enhanced Tissue Regeneration.

Journal of biomedical materials research. Part A·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14⁺ Monocytes

Published on: April 11, 2025

Biomaterial-Focused Strategies Targeting Dendritic Cells for Autoimmune Disease Treatment.

Aiswarya Venkata Suresh Kumar¹, Julia Babensee²

¹Wallace H. Coulter Department of Biomedical Engineering, Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA.

Journal of Biomedical Materials Research. Part A

|June 23, 2026

Summary

Engineered biomaterials offer new ways to deliver tolerogenic dendritic cells (tolDCs) for autoimmune diseases. These materials improve cell delivery and immune modulation, overcoming challenges in current treatments.

Keywords:

autoimmune diseases biomaterials hydrogels immune modulation microparticles nanoparticles scaffolds tissue engineering tolerogenic dendritic cells

More Related Videos

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14⁺ Monocytes

Published on: April 11, 2025

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

Immunology
Biomaterials Science
Nanotechnology

Background:

Autoimmune diseases affect millions, with current treatments focusing on symptom management rather than cures.
Tolerogenic dendritic cells (tolDCs) show promise for restoring immune balance but face clinical translation challenges.
Existing delivery methods for tolDCs result in suboptimal distribution, rapid clearance, and instability.

Purpose of the Study:

To review recent advances in biomaterial-based delivery systems for dendritic cell (DC) therapies.
To explore how biomaterials can overcome challenges in tolDC clinical translation for autoimmune diseases.
To highlight the potential of biomaterials in redefining therapeutic strategies for immune-mediated conditions.

Main Methods:

Review of engineered biomaterials (nanoparticles, microparticles, hydrogels, scaffolds) for DC delivery.
Analysis of biomaterial platforms for targeted delivery of ex vivo-generated tolDCs or in situ reprogramming of endogenous DCs.
Evaluation of biomaterial properties including tunable release kinetics, targeting specificity, and immune response modulation.

Main Results:

Biomaterials enable targeted delivery and in situ reprogramming of DCs, addressing limitations of conventional methods.
Engineered platforms offer improved safety profiles, enhanced potency, and controlled release kinetics.
Biomaterials can modulate immune responses, shifting from inflammation towards immune tolerance for sustained disease management.

Conclusions:

Biomaterial-based delivery systems represent a promising alternative to conventional administration for DC therapies.
These platforms hold significant potential to overcome current hurdles in tolDC clinical translation.
Advancements in biomaterials could redefine therapeutic strategies for autoimmune diseases, moving towards prevention and cure.